Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 April 2021Next earnings report:
21 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 5 min agoDividend
Analysts recommendations
Institutional Ownership
CMPX Latest News
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.
Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The heavy selling pressure might have exhausted for Compass Therapeutics, Inc. (CMPX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
What type of business is Compass Therapeutics?
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
What sector is Compass Therapeutics in?
Compass Therapeutics is in the Healthcare sector
What industry is Compass Therapeutics in?
Compass Therapeutics is in the Biotechnology industry
What country is Compass Therapeutics from?
Compass Therapeutics is headquartered in United States
When did Compass Therapeutics go public?
Compass Therapeutics initial public offering (IPO) was on 05 April 2021
What is Compass Therapeutics website?
https://www.compasstherapeutics.com
Is Compass Therapeutics in the S&P 500?
No, Compass Therapeutics is not included in the S&P 500 index
Is Compass Therapeutics in the NASDAQ 100?
No, Compass Therapeutics is not included in the NASDAQ 100 index
Is Compass Therapeutics in the Dow Jones?
No, Compass Therapeutics is not included in the Dow Jones index
When was Compass Therapeutics the previous earnings report?
No data
When does Compass Therapeutics earnings report?
The next expected earnings date for Compass Therapeutics is 21 March 2025